Chembio Diagnostics (NASDAQ:CEMI) – Zacks Investment Research issued their Q1 2018 earnings estimates for Chembio Diagnostics in a research report issued to clients and investors on Tuesday, March 13th, according to Zacks Investment Research. Zacks Investment Research analyst B. Marckx expects that the company will post earnings of ($0.10) per share for the quarter. Zacks Investment Research also issued estimates for Chembio Diagnostics’ Q2 2018 earnings at ($0.08) EPS, Q3 2018 earnings at ($0.08) EPS, Q4 2018 earnings at ($0.04) EPS and FY2020 earnings at $0.11 EPS.
Separately, ValuEngine raised shares of Chembio Diagnostics from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd.
NASDAQ CEMI traded down $0.10 during trading hours on Friday, reaching $7.90. 11,529 shares of the company’s stock traded hands, compared to its average volume of 22,347. Chembio Diagnostics has a 52-week low of $5.25 and a 52-week high of $9.20. The stock has a market cap of $113.30, a P/E ratio of -15.19 and a beta of 1.18. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.51 and a quick ratio of 2.08.
Chembio Diagnostics (NASDAQ:CEMI) last issued its quarterly earnings results on Thursday, March 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.06). Chembio Diagnostics had a negative net margin of 27.56% and a negative return on equity of 41.95%. The business had revenue of $5.99 million for the quarter, compared to analysts’ expectations of $5.66 million.
Institutional investors have recently modified their holdings of the business. Goldman Sachs Group Inc. purchased a new position in Chembio Diagnostics in the second quarter worth about $151,000. Benchmark Capital Advisors raised its holdings in Chembio Diagnostics by 101.9% in the fourth quarter. Benchmark Capital Advisors now owns 66,417 shares of the company’s stock worth $545,000 after buying an additional 33,517 shares during the last quarter. Finally, Royce & Associates LP raised its holdings in Chembio Diagnostics by 367.6% in the fourth quarter. Royce & Associates LP now owns 102,400 shares of the company’s stock worth $840,000 after buying an additional 80,500 shares during the last quarter. 31.23% of the stock is owned by institutional investors and hedge funds.
In other news, CFO Neil A. Goldman bought 14,815 shares of the firm’s stock in a transaction on Tuesday, February 13th. The stock was acquired at an average cost of $6.75 per share, with a total value of $100,001.25. Following the completion of the acquisition, the chief financial officer now owns 14,815 shares of the company’s stock, valued at $100,001.25. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 5.56% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Chembio Diagnostics Expected to Earn Q1 2018 Earnings of ($0.10) Per Share (NASDAQ:CEMI)” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/04/07/q1-2018-earnings-estimate-for-chembio-diagnostics-inc-issued-by-zacks-investment-research-cemi.html.
Chembio Diagnostics Company Profile
Chembio Diagnostics, Inc, together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or monitor diseases. It offers tests for HIV and Syphilis, and Zika virus. The company also develops tests for malaria, Dengue virus, chikungunya virus, Ebola, Lassa, Marburg, leptospirosis, Rickettsia typhi, Burkholderia pseudomallei, and Orientia tsutsugamushi.
Get a free copy of the Zacks research report on Chembio Diagnostics (CEMI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Chembio Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chembio Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.